Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies

Autor: Sanna Iivanainen, Jussi Ekstrom, Henri Virtanen, Vesa V. Kataja, Jussi P. Koivunen

Publikováno v: BMC Medical Informatics and Decision Making, Vol 21, Iss 1, Pp 1-8 (2021)

Abstract Background Immune-checkpoint inhibitors (ICIs) have introduced novel immune-related adverse events (irAEs), arising from various organ systems without strong timely dependency on therapy dosing. Early detection of irAEs could result in impro

Externí odkaz: https://doaj.org/article/bbc616ea2edc46f6bd8e030ee67dcf98

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies

Autor: Henri Virtanen, Sanna Iivanainen, Vesa V. Kataja, Jussi Ekström, Jussi Koivunen

Publikováno v: BMC Medical Informatics and Decision Making
BMC Medical Informatics and Decision Making, Vol 21, Iss 1, Pp 1-8 (2021)

Background Immune-checkpoint inhibitors (ICIs) have introduced novel immune-related adverse events (irAEs), arising from various organ systems without strong timely dependency on therapy dosing. Early detection of irAEs could result in improved toxic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a82d64a9617f6bb8a95276e5df4d0c65
http://europepmc.org/articles/PMC8243435

Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer

Autor: Egils Vjaters, Karim Fizazi, Nicholas D. James, Teuvo Tammela, Nobuaki Matsubara, Frank Priou, Thierry Lesimple, Petri Bono, Vesa V Kataja, Jorge A. Garcia, Andrew Protheroe, John Aspegren, Heikki Joensuu, Iris Kuss, Silke Thiele, Sabine Fiala-Buskies, Robert Hugh Jones

Publikováno v: Journal of Clinical Oncology. 40:90-90

90 Background: Darolutamide, a structurally distinct and highly potent androgen receptor inhibitor, had a consistently favorable safety and tolerability profile in patients with nonmetastatic castration-resistant prostate cancer in ARAMIS, and discon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9516a40be0b612ac2ae915de0285c06
https://doi.org/10.1200/jco.2022.40.6_suppl.090

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.

Autor: Jones RH; Cardiff University and Velindre Cancer Centre, Cardiff, UK. Robert.Hugh.Jones@wales.nhs.uk., Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., James ND; The Institute of Cancer Research, London, UK., Tammela TL; Tampere University Hospital, Tampere, Finland., Matsubara N; National Cancer Center Hospital East, Chiba, Japan., Priou F; Centre Hospitalier Départemental Vendée, La Roche-Sur-Yon, France., Beuzeboc P; Curie Institute, Paris, France., Lesimple T; Centre Eugène Marquis, Rennes, France., Bono P; Terveystalo Finland and University of Helsinki, Helsinki, Finland., Kataja V; Kuopio University Hospital, Kuopio, Finland., Garcia JA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA., Protheroe A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Shore N; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA., Aspegren J; Orion Corporation, Espoo, Finland., Joensuu H; Orion Corporation, Espoo, Finland., Kuss I; Bayer AG, Berlin, Germany., Fiala-Buskies S; Bayer AG, Wuppertal, Germany., Vjaters E; P. Stradins Clinical University Hospital, Riga, Latvia.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Dec; Vol. 27 (4), pp. 786-789. Date of Electronic Publication: 2023 Oct 26.

A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland.

Autor: Ollila E; Cancer Society of Finland, P.O. Box 238, 00131, Helsinki, Finland. eeva.ollila@cancer.fi.; Faculty of Social Sciences, University of Tampere, Tampere, Finland. eeva.ollila@cancer.fi., Kataja V; Kaiku Health, Part of ELEKTA, Helsinki, Finland.; University of Eastern Finland, Jyväskylä, Finland., Sailas L; Cancer Center, Joint Municipal Authority for North Karelia Social and Health Care Services (SiunSote), Joensuu, Finland.

Publikováno v: Journal of pharmaceutical policy and practice [J Pharm Policy Pract] 2022 Aug 29; Vol. 15 (1), pp. 52. Date of Electronic Publication: 2022 Aug 29.